## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.1% below STRENGTH zone (4.0-10.0%); PEG 1.64 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($35.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 2)

**1. Guidance Cut From Higher Exchange Costs Could Be A Game Changer For Centene (CNC)**
- Source: Simply Wall Street | 20251204T200857 | Bearish | Relevance: 100%
- Centene (CNC) has cut its earnings guidance due to higher-than-expected medical utilization in its federal exchange plans and ongoing pressure in its Medicaid business. This adjustment raises concerns that potential changes to federal exchange subsidy policy could lead to a smaller, sicker enrollee base, putting additional pressure on profitability and reshaping Centene's investment narrative. The company's updated 2025 outlook now anticipates a GAAP diluted loss per share not exceeding US$12.85, impacting its short-term earnings recovery prospects.

**2. Invesco Ltd. Purchases 633,946 Shares of Centene Corporation $CNC**
- Source: MarketBeat | 20251204T120816 | Neutral | Relevance: 100%
- Invesco Ltd. increased its holdings in Centene Corporation by 5.7%, acquiring an additional 633,946 shares, bringing its total ownership to 11,725,910 shares valued at approximately $636.5 million. Centene reported strong Q3 earnings, beating analyst expectations with $0.50 EPS and $49.69 billion in revenue, showing an 18.2% year-over-year revenue increase. The company currently holds an average analyst "Hold" rating with a consensus target price of $40.00.

**3. Is Centene Stock Underperforming the S&P 500?**
- Source: Markets Financial Content | 20251204T073700 | Neutral | Relevance: 100%
- Centene Corporation (CNC) stock has dropped 41.9% from its 52-week high, underperforming the S&P 500 Index (SPX) on a YTD and 52-week basis, despite a recent 29.1% gain over the past three months and a significant jump after raising its 2025 adjusted profit forecast. Analysts maintain a "Hold" rating due to its weak performance.

**4. Centene Corp. stock underperforms Monday when compared to competitors**
- Source: MSN | 20251202T150817 | Somewhat-Bearish | Relevance: 100%
- Centene Corp. stock experienced an underperformance on Monday compared to its competitors. The stock closed down while its rivals saw gains, reflecting a mixed day in the market for healthcare companies. This suggests potential volatility or specific company-related factors influencing Centene's performance relative to the broader sector.

**5. Hereâ€™s Why Centene Corporation (CNC) Reduced Its Earnings Outlook**
- Source: MSN | 20251204T060818 | Bearish | Relevance: 100%
- Centene Corporation (CNC) has reduced its earnings outlook, leading to investor concern. This revision often indicates challenges in operations or market conditions that impact the company's profitability. Analysts and investors will closely monitor Centene's future reports for further insights into its performance.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |
| 2025-11-12 | Wells Fargo | $35 | $41 | -15% |
| 2025-11-04 | JP Morgan | $38 | $30 | +27% |
| 2025-11-04 | Barclays | $44 | $35 | +26% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |
| 2025-11-12 | Wells Fargo | main | Equal-Weight |
| 2025-11-04 | JP Morgan | main | Neutral |
| 2025-11-04 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Long-term trend broken: trading 12.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +26%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.64 elevated, pricing in significant growth expectations. Forward P/E 13.4x attractive for 43% earnings growth. Balance sheet: $1.1B free cash flow. Analyst sentiment positive (3 raises, avg +26%). Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.9B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.64 |
| Forward P/E | 13.4 |
| Current P/E | 19.2 |
| YoY Growth | 43.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 5.8% to 2.1% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.9pp (needs >4.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.3% shows strong absolute momentum above own 20MA. Outperforming sector by 3.6pp, stock-specific strength. Below SMA200 (0.87x), long-term trend not supportive. RSI neutral at 58. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.11% (CS: 69) | Neutral |
| RSI_14 | 58.1 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.043x | Above |
| vs SMA50 | 1.066x | Above |
| vs SMA200 | 0.873x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $38.85
- **Stop Loss:** $35.91 (7.6% risk)
- **Target:** $41.79 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 170
- **Position Value:** $6,604.50
- **Portfolio %:** 6.60%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*